DFX Intelligence

Data Factory

VentureFirmmulti stage vc · probableexempt_reporting_adviser

Sofinnova Partners

Venture Capital

Paris

Sofinnova Partners invests in life sciences innovation worldwide, from biopharma and medtech to digital medicine and industrial biotech.

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:0f1ad0c1-c933-4d47-bdf3-65f457d300b7

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 11:37 PM UTC and rebuilt at most every 15 minutes.

Relationships: 244
Dated events: 27
On other graphs: 1
Observed: Sep 12, 2026 to Sep 17, 2026
49 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Private Equityidentity

Sofinnova Partners

Private equity manager · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 17
Vintages: 2013 to 2023
Reported GAV: $1.6Bgross asset value on Form ADV; never dry powder
Funds with fundraising evidence: 0derived
Investments: 150
Portfolio companies: 149
Investments, 12m: 149
Partner-attributed: 2
People: 72
Investment professionals: 50derived
Co-investors: 0derived
LP relationships: 0
Stated sectors: healthcare,biotech,medtech,climate,industrial,agtechas stated by the firm
Stated stages: seed,growth,early
Stated geography: europe
Latest ADV filing: Mar 28, 2024
Website: sofinnovapartners.com

Funds

Fund	Vintage	Lifecycle	Form D sold	GAV
Sofinnova Digital Medicine I	2023	Active deployment	n/a	$41.9M
Sofinnova Industrial Biotech II	2022	Active deployment	n/a	$38.6M
Sofinnova Capital X	2022	Active deployment	n/a	$113M
Sofinnova MD Start III	2020	Mature	n/a	$99.8M
Sofinnova Coiv Eif	2020	Mature	n/a	$12.1M
Sofinnova IT	2019	Mature	n/a	$53.5M
Sofinnova Telethon Sca Raif	2019	Mature	n/a	$66.7M
Sofinnova Capital Ix	2019	Mature	n/a	$222M
Sofinnova Crossover I	2019	Mature	n/a	$324M
Sofinnova Industrial Biotech I	2018	Harvest	n/a	$106M
Sofinnova Capital Viii	2016	Harvest	n/a	$271M
Sofinnova Capital VII	2013	Harvest	n/a	$112M
Sofinnova Green Seed Fund	2013	Harvest	n/a	$48.9M
Sofinnova Capital III	n/a	Wound down	n/a	$1.3M
Sofinnova Capital VI	n/a	Unknown	n/a	$78.4M
Sofinnova Capital V	n/a	Unknown	n/a	$4.9M
Sofinnova Capital IV	n/a	Wound down	n/a	$20.0M

Investments

round size is never this investor's check

Company	State	Stage	Round size	Partner	Attribution	Observed
Excelsior Sciences	n/a	n/a	n/a	n/a	Unknown	Sep 20, 2026
Crescendo Biologics	n/a	n/a	n/a	n/a	Unknown	Sep 17, 2026
Crossover Abivax	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
ABIONYX Pharma	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Telethon Alia Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Capital Ablynx NV	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Addex Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Capital Asceneuron	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Advanced Perfusion Diagnostics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Industrial Biotech Afyren	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Industrial Biotech Biosyntia	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Crossover Amolyt Pharma	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Crossover Artios Pharma	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Industrial Biotech Arzeda	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Capital Ascendis Pharma	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Capital Actithera	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Industrial Biotech Avantium	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Digital Medicine Betteromics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Biovelocita BioClec	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Digital Medicine BioCorteX	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Bionyra	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Digital Medicine Bioptimus	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Pi-Cardia	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Industrial Biotech Biotalys	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Telethon AAVantgarde Bio	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026

Co-investors

pairs come only from shared rounds and listings

Investor	Co-investor	Shared deals	Shared companies	Last observed	Strength
Sofinnova Investments, Inc.	Sofinnova Partners	2	2	Sep 16, 2026	Recurring
Sofinnova Partners	Andera Partners	1	1	Sep 17, 2026	One time
Sofinnova Partners	Future Planet Capital Limited	1	1	Sep 17, 2026	One time
Sofinnova Partners	Deep Track Capital	1	1	Oct 27, 2025	One time
Sofinnova Partners	Invus	1	1	Oct 27, 2025	One time
Sofinnova Partners	Access Biotechnology	1	1	Oct 27, 2025	One time
Sofinnova Partners	Novo Holdings	1	1	Oct 27, 2025	One time
Sofinnova Partners	Maj Invest Equity	1	1	Oct 27, 2025	One time
Sofinnova Partners	Clark Partners	1	1	May 26, 2026	One time
Sofinnova Partners	Emerald Technology Ventures	1	1	May 26, 2026	One time
Sofinnova Partners	Elm Street Ventures	1	1	May 26, 2026	One time
Sofinnova Partners	Connecticut Innovations	1	1	May 26, 2026	One time
Sofinnova Partners	HealthCap	1	1	Oct 27, 2025	One time
Sofinnova Partners	Basf	1	1	May 26, 2026	One time
Sofinnova Partners	Chanel	1	1	May 26, 2026	One time

Relationships

showing 80 of 244

Invested in (79)

→ Excelsior SciencesCompanyPortfolio listing
Sep 20, 2026 to presentfactThe subject's own site
→ Crescendo BiologicsCompanyPortfolio listing
Sep 17, 2026 to presentfactThe subject's own site
→ Digital Medicine L'école AICompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital ENYO PharmaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital Haya TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Digital Medicine KiroCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital Corvidia TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Telethon Borea TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital DISCO PharmaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital Enthera PharmaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital GalvanizeCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ MD Start Gradient Denervation TechnologiesCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital HotSpot TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ MD Start Julier MedicalCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Digital Medicine BetteromicsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Crossover Artios PharmaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital CinCor PharmaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital CorVent MedicalCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Digital Medicine Cure51CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ DeliniaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital Elevara MedicinesCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Industrial Biotech EnginZymeCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Digital Medicine Excelsior SciencesCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital Freya BiosciencesCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Crossover GenSight BiologicsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital GlycoVaxynCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ MD Start HEPTA MedicalCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital Hookipa PharmaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ InotremCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Capital iOmx TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
and 49 more

Dated events

19 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Oct 17, 2022
Person left
Denis Lucquin (Partner) no longer on Schedule A of Sofinnova Partners
Form ADVobserved 8 days ago
Occurred
Oct 1, 2022
Person joined
Mats Kristian Eklund joined Schedule A of Sofinnova Partners as Chief Operating Officer
Form ADVobserved 8 days ago
Occurred
Jun 16, 2020
Person left
Rafaele Tordjman (Managing Partner) no longer on Schedule A of Sofinnova Partners
Form ADVobserved 8 days ago
Occurred
Jun 16, 2020
Person left
Jean Bernard Schmidt (Retired) no longer on Schedule A of Sofinnova Partners
Form ADVobserved 8 days ago
Occurred
Sep 1, 2014
Person joined
Henrijette Richter joined Schedule A of Sofinnova Partners as Managing Partner
Form ADVobserved 8 days ago
Occurred
May 9, 2012
Adviser's first ADV filing
Sofnnova Partners first filed Form ADV (ERA, venture capital fund adviser exemption)
Form ADVobserved 8 days ago
Occurred
Apr 1, 2012
Person joined
Graziano Seghezzi joined Schedule A of Sofinnova Partners as Managing Partner
Form ADVobserved 8 days ago
Occurred
Apr 1, 2012
Person joined
Graziano Seghezzi joined Schedule A of Sofinnova Partners as Managing Partner
Form ADVobserved 8 days ago

Show 19 bookkeeping events

Occurred
Mar 22, 2023
Sofinnova Digital Medicine I first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $22,570,567
Occurred
Mar 30, 2022
Sofinnova Capital X first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $21,228,416
Occurred
Mar 30, 2022
Sofinnova Industrial Biotech II first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $23,558,987
Occurred
Jun 16, 2020
Sofinnova Coiv Eif first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $3,184,112
Occurred
Jun 16, 2020
Sofinnova MD Start III first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $3,190,250
Occurred
Jun 16, 2020
Sofinnova Capital IV no longer reported on Form ADV by Sofinnova Partners
Occurred
Jun 21, 2019
Sofinnova Telethon Sca Raif first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $3,000,000
Occurred
Jun 21, 2019
Sofinnova Crossover I first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $25,000,000
Occurred
Jun 21, 2019
Sofinnova IT first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $64,000,000
Occurred
Jun 21, 2019
Sofinnova Capital Ix first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $15,000,000
Occurred
Apr 13, 2018
Sofinnova Capital III no longer reported on Form ADV by Sofinnova Partners
Occurred
Apr 13, 2018
Sofinnova Industrial Biotech I first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $5,000,000
Occurred
Jun 28, 2016
Sofinnova Capital Viii first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $28,100,000
Occurred
Aug 30, 2013
Sofinnova Capital VII first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $15,000,000
Occurred
Aug 30, 2013
Sofinnova Green Seed Fund first reported on Form ADV by Sofinnova Partners (Venture Capital Fund), GAV $3,000,000
Occurred
May 9, 2012
Sofinnova Capital VI first reported on Form ADV by Sofnnova Partners (Venture Capital Fund), GAV $192,000,000
Occurred
May 9, 2012
Sofinnova Capital III first reported on Form ADV by Sofnnova Partners (Venture Capital Fund), GAV $10,000,000
Occurred
May 9, 2012
Sofinnova Capital IV first reported on Form ADV by Sofnnova Partners (Venture Capital Fund), GAV $136,000,000
Occurred
May 9, 2012
Sofinnova Capital V first reported on Form ADV by Sofnnova Partners (Venture Capital Fund), GAV $446,000,000

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 2 websites (Form ADV) · as of 2026-09-12

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Venture Capital
Canonical id: dfx:vc:0f1ad0c1-c933-4d47-bdf3-65f457d300b7
First observed: Sep 12, 2026
Last observed: Sep 17, 2026 3 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
2 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Sofinnova Partners

Venture Capital

Paris

Sofinnova Partners invests in life sciences innovation worldwide, from biopharma and medtech to digital medicine and industrial biotech.

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:0f1ad0c1-c933-4d47-bdf3-65f457d300b7

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 20, 2026, 11:37 PM UTC and rebuilt at most every 15 minutes.